百奥泰(688177)
 
 
  日线
顶尖财经网欢迎您!
  K线
 
 最新动态
  投资评级

研究机构 评级日期 最新评级 上次评级
上海证券 2024-01-22 买入
中信建投 2023-12-22 买入 买入
德邦证券 2023-12-01 买入
  盈利预测
据百奥泰三季报分析:

  盈利能力维持稳定,主营获利能力有明显提升

  成长能力有所加强,公司规模结束收缩开始扩张

  偿债能力维持稳定,短期债务风险存在但可以控制

  运营能力维持稳定,资金使用效率得到显著提高

  现金流能力维持稳定,公司资金流转压力稍有增加

  财务数据
    截至第三季度实现净利润-3.82亿元,每股收益-0.92元。

    截至第三季度最新股东权益122512.75万元,未分配利润-224340.17万元。

    截至第三季度最新总资产233350.16万元,负债110837.41万元。

利润表
报告期2023-09-302023-06-302023-03-312022-12-31
营业总收入461,050,213.9314,666,473.81154,927,728.15455,131,950.13
营业总成本879,482,469.75599,342,796.17323,385,023.77978,089,575.12
营业利润-377,401,839.61-248,830,511.51-139,494,174.41-462,797,768.53
利润总额-382,180,237.12-253,620,873.26-142,581,598.84-480,396,726.11
净利润-382,180,237.12-253,620,873.26-142,584,813.68-480,398,851.59
其他综合收益52,531.6366,881.24-21,152.05141,856.96
综合收益总额-382,127,705.49-253,553,992.02-142,605,965.73-480,256,994.63
资产负债表
报告期2023-09-302023-06-302023-03-312022-12-31
流动资产合计1,077,255,977.491,152,923,864.611,242,157,477.741,162,259,116.86
非流动资产合计1,256,245,615.741,130,371,883.771,090,503,7841,017,477,818.99
资产总计2,333,501,593.232,283,295,748.382,332,661,261.742,179,736,935.85
流动负债合计768,652,943.99687,867,210.7582,653,895.81538,503,100.22
非流动负债合计339,721,139.65241,727,314.62285,358,116.5833,978,620.55
负债合计1,108,374,083.64929,594,525.32868,012,012.39572,481,720.77
归属于母公司股东权益合计1,225,127,509.591,353,701,223.061,464,649,249.351,607,255,215.08
股东权益合计1,225,127,509.591,353,701,223.061,464,649,249.351,607,255,215.08
负债和股东权益合计2,333,501,593.232,283,295,748.382,332,661,261.742,179,736,935.85
现金流量表
报告期2023-09-302023-06-302023-03-312022-12-31
经营活动现金流入小计576,005,249.76391,982,890.66186,030,998.54610,827,499.08
经营活动现金流出小计934,151,429.86610,669,776.25332,184,512.081,023,645,025.89
经营活动产生的现金流量净额-358,146,180.1-218,686,885.59-146,153,513.54-412,817,526.81
投资活动现金流入小计1,557,960,978.921,145,141,626672,120,639.694,033,292,160.26
投资活动现金流出小计1,418,094,540.641,059,448,613.86562,154,732.724,279,088,740.07
投资活动产生的现金流量净额139,866,438.2885,693,012.14109,965,906.97-245,796,579.81
筹资活动现金流入小计427,648,244.22250,107,688.84250,092,036.043,000,000
筹资活动现金流出小计30,760,761.525,852,178.941,403,871.5233,154,800.38
筹资活动产生的现金流量净额396,887,482.7244,255,509.9248,688,164.52-30,154,800.38
汇率变动对现金及现金等价物的影响638,579.39601,151.98-116,855.74766,366.5
现金及现金等价物净增加额179,246,320.27111,862,788.43212,383,702.21-688,002,540.5
期末现金及现金等价物余额324,644,281.22257,260,749.38357,781,663.16145,397,960.95
  主营收入+营业利润
 
  净利润+每股收益
  股东权益+未分配利润
 
  总资产+负债
  投资要点

    截至第三季度实现净利润-3.82亿元,每股收益-0.92元。

    截至第三季度最新股东权益122512.75万元,未分配利润-224340.17万元。

    截至第三季度最新总资产233350.16万元,负债110837.41万元。

利润表
报告期2023-09-302023-06-302023-03-312022-12-31
营业总收入461,050,213.9314,666,473.81154,927,728.15455,131,950.13
营业总成本879,482,469.75599,342,796.17323,385,023.77978,089,575.12
营业利润-377,401,839.61-248,830,511.51-139,494,174.41-462,797,768.53
利润总额-382,180,237.12-253,620,873.26-142,581,598.84-480,396,726.11
净利润-382,180,237.12-253,620,873.26-142,584,813.68-480,398,851.59
其他综合收益52,531.6366,881.24-21,152.05141,856.96
综合收益总额-382,127,705.49-253,553,992.02-142,605,965.73-480,256,994.63
资产负债表
报告期2023-09-302023-06-302023-03-312022-12-31
流动资产合计1,077,255,977.491,152,923,864.611,242,157,477.741,162,259,116.86
非流动资产合计1,256,245,615.741,130,371,883.771,090,503,7841,017,477,818.99
资产总计2,333,501,593.232,283,295,748.382,332,661,261.742,179,736,935.85
流动负债合计768,652,943.99687,867,210.7582,653,895.81538,503,100.22
非流动负债合计339,721,139.65241,727,314.62285,358,116.5833,978,620.55
负债合计1,108,374,083.64929,594,525.32868,012,012.39572,481,720.77
归属于母公司股东权益合计1,225,127,509.591,353,701,223.061,464,649,249.351,607,255,215.08
股东权益合计1,225,127,509.591,353,701,223.061,464,649,249.351,607,255,215.08
负债和股东权益合计2,333,501,593.232,283,295,748.382,332,661,261.742,179,736,935.85
现金流量表
报告期2023-09-302023-06-302023-03-312022-12-31
经营活动现金流入小计576,005,249.76391,982,890.66186,030,998.54610,827,499.08
经营活动现金流出小计934,151,429.86610,669,776.25332,184,512.081,023,645,025.89
经营活动产生的现金流量净额-358,146,180.1-218,686,885.59-146,153,513.54-412,817,526.81
投资活动现金流入小计1,557,960,978.921,145,141,626672,120,639.694,033,292,160.26
投资活动现金流出小计1,418,094,540.641,059,448,613.86562,154,732.724,279,088,740.07
投资活动产生的现金流量净额139,866,438.2885,693,012.14109,965,906.97-245,796,579.81
筹资活动现金流入小计427,648,244.22250,107,688.84250,092,036.043,000,000
筹资活动现金流出小计30,760,761.525,852,178.941,403,871.5233,154,800.38
筹资活动产生的现金流量净额396,887,482.7244,255,509.9248,688,164.52-30,154,800.38
汇率变动对现金及现金等价物的影响638,579.39601,151.98-116,855.74766,366.5
现金及现金等价物净增加额179,246,320.27111,862,788.43212,383,702.21-688,002,540.5
期末现金及现金等价物余额324,644,281.22257,260,749.38357,781,663.16145,397,960.95
  十大流通股东
十大流通股东 报告期:2023-09-30
股东名称 持股数量(万股) 占总股本比例(%) 上期持股变化(万股)
广州七喜集团有限公司15947.1238.516.66
Therabio International Limited4717.7711.390.00
广州启奥兴投资合伙企业(有限合伙)2317.335.600.00
广州中科粤创孵化器投资管理有限公司-广州中科粤创三号创业投资合伙企业(有限合伙)2133.335.150.00
广州兴昱投资合伙企业(有限合伙)2132.005.150.00
东台市启恒医药合伙企业(有限合伙)2042.344.93-107.61
广州晟昱投资合伙企业(有限合伙)1600.003.860.00
广州返湾湖投资合伙企业(有限合伙)742.461.790.00
SHENGFENG LI651.731.570.00
汇天泽投资有限公司456.091.100.00
  主力控盘
  公司简介
百奥泰 所属地域: 广东省 涉及概念: 沪股通,创新药,生物医药,融资融券
主营业务: 医学研究和试验发展;技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广;细胞技术研发和应用;药品委托生产;药品生产;货物进出口;技术进出口;药品进出口;药品零售。
上市日期: 2020-02-21 每股净资产: 2.96元 每股收益: -0.92元 净利润: -3.82亿元 净利润增长率: -49.51%
营业收入: 4.61亿元 每股现金流: -0.86元 每股公积金: 7.38元 每股未分配利润: -5.42元 总股本: 4.14亿 流通股: 4.14亿
以上信息为合作方、加盟公司及会员收集,本站不拥有版权,版权归原作者所有,所载文章、数据仅供参考,据此操作,风险自负。

中 华 顶 尖 财 经 -- 中 华 顶 尖 网 络 信 息 服 务 中 心